



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent  
Licensee of the Blue Cross and Blue Shield Association

## Medical Policy

# Esophagogastroduodenoscopy (EGD)/Upper Gastrointestinal Endoscopy

### Table of Contents

- [Policy: Commercial](#)
- [Coding Information](#)
- [Information Pertaining to All Policies](#)
- [Policy: Medicare](#)
- [Description](#)
- [References](#)
- [Authorization Information](#)
- [Policy History](#)
- [Endnotes](#)

### Policy Number: 202

BCBSA Reference Number: N/A

NCD/LCD: N/A

### Related Policies

- Adjunctive Techniques for Screening and Surveillance of Barrett Esophagus and Esophageal Dysplasia [#841](#)
- Chromoendoscopy as an Adjunct to Colonoscopy [#904](#)
- Endoscopic Radiofrequency Ablation or Cryoablation for Barretts Esophagus [#218](#)
- Medical and Surgical Management of Obesity including Anorexiant [#379](#)
- Serological Diagnosis of Celiac Disease [#138](#)
- Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease [#551](#)
- Surgical and Transesophageal Endoscopic Procedures to Treat Gastroesophageal Reflux Disease [#920](#)
- Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders [#185](#)

### Policy<sup>1</sup>

## Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members

Esophagogastroduodenoscopy (EGD)/Upper Gastrointestinal Endoscopy is considered **MEDICALLY NECESSARY** for the following:

### Evaluation and Diagnosis

- **Symptoms**
  - Upper abdominal symptoms (e.g., dyspepsia, heartburn, regurgitation, non-cardiac pain, nausea)
    - Recent onset symptoms in patients >50 years.
    - Associated with anorexia, early satiety, weight loss, GI bleeding.
    - If under age 50, symptoms >8 weeks and refractory to medical acid suppression **AND** negative non-invasive H. pylori testing (e.g., stool antigen, urea breath test)
  - Dysphagia, odynophagia, or food impaction.
  - Persistent vomiting of unknown cause.
  - GI bleeding:

- Active or recent bleeding (e.g., hematemesis, melena).
- Presumed chronic blood loss with iron deficiency (with or without anemia) when upper GI source suspected or colonoscopy negative.
- **Suspected or Diagnosed Conditions:**
  - Acute caustic ingestion for injury assessment and management
  - Esophagitis
  - Upper GI obstruction or stricture.
  - Radiologically demonstrated lesions requiring histologic confirmation (e.g., mass, neoplastic lesions, ulcers, strictures).
  - Esophageal cancer post-resection with signs/symptoms of local/regional recurrence.
  - Portal hypertension with or without cirrhosis to assess for esophageal varices.
  - Celiac disease (suspected or for confirmation).
  - Differentiation of Crohn's disease from ulcerative colitis.
  - Conditions requiring upper GI fluid sampling or tissue biopsy for diagnosis/evaluation.
  - Esophageal physiology assessment using impedance planimetry.
  - Placement of wireless pH capsule for esophageal/extraesophageal reflux symptoms without severe erosive reflux disease.

### Treatment and Management

- Removal of foreign bodies or polypoid lesions.
- Treatment of bleeding lesions (e.g., ulcers, tumors, vascular anomalies) via:
  - Electrocoagulation, heat probe, laser, or injection therapy.
  - Banding or sclerotherapy of esophageal varices.
- Dilation of stenotic lesions.
- Palliative treatment of stenosing neoplasms (e.g., laser, electrocoagulation, stent placement).
- Eosinophilic esophagitis or eosinophilic GI diseases for disease activity assessment and management.
- Achalasia management.
- Placement of feeding or drainage tubes (e.g., peroral, percutaneous endoscopic gastrostomy, jejunostomy).
- Endoscopic therapy for Barrett's esophagus and/or gastric intestinal metaplasia.

### Screening for High-Risk Conditions

- **Barrett's Esophagus:**
  - Chronic GERD ( $\geq 5$  years) without known Barrett's; repeat screening not necessary if first EGD is negative.
  - Severe erosive esophagitis to assess for mucosal healing and screen for Barrett's esophagus. No longer necessary when mucosa is healed and if initial screen for Barrett's is negative
- **Gastric/Duodenal Polyps in Familial Adenomatous Polyposis (FAP):**
  - Confirmed FAP by genetic testing at first detection of colonic polyps or age 25
  - High-risk for FAP (without genetic testing or with indeterminate results):
    - i. First-degree relatives of FAP patients.
    - OR**
    - ii.  $> 10$  cumulative colorectal adenomas.
    - OR**
    - Colorectal adenomas with extracolonic FAP manifestations (e.g., duodenal/ampullary adenomas, desmoid tumors, thyroid carcinoma, retinal hamartomas, cysts, osteomas).
    - Screening is **NOT MEDICALLY NECESSARY** for categories i and ii above **if genetic testing shows the absence of pathogenic APC gene variants.**
- **Gastric/Duodenal Polyps in MUTYH-associated Polyposis (MAP):**
  - Begins at age 30–35 years for individuals with confirmed biallelic MUTYH mutations.

### Surveillance of High-Risk Conditions

- **Esophageal Cancer:**
  - Barrett's esophagus:

- High-grade dysplasia: Every 3 months.
  - Low-grade dysplasia: Yearly.
  - No dysplasia: Every 3 years.
- Tylosis (Howel-Evans syndrome): Starting at age 30 (or earlier if family member developed cancer at a younger age), every 1-3 years.
- Severe esophageal injury from caustic ingestion: Starting 10-20 years post-ingestion, every 2-3 years.
- **Upper GI Polyps/Cancers in FAP and MAP:**
  - If the initial EGD is normal (no polyps or significant findings), repeat EGD every **4 years**.
  - If gastric or duodenal polyps are detected, surveillance intervals are adjusted based on the **Spigelman classification** for duodenal polyposis\*, which assesses polyp number, size, histology, and dysplasia:
    - **Stage 0 (no polyps)**: EGD every 4 years.
    - **Stage I (mild polyposis)**: EGD every 2–3 years.
    - **Stage II**: EGD every 1–3 years.
    - **Stage III**: EGD every 6–12 months.
    - **Stage IV (severe polyposis)**: EGD every 3–6 months.
    - For gastric fundic gland polyps, surveillance is typically aligned with duodenal findings.
- **Gastric Cancer**
  - Gastric intestinal metaplasia (GIM) with risk factors below should have repeat EGD every 3 years.
    - Family history of gastric cancer in a first-degree relative
    - Incomplete GIM
    - Extensive or corpus GIM
    - Racial/ethnic minorities in the United States (including African Americans, Hispanics, and Asians)
    - First-generation immigrants from high-incidence areas (eg, Eastern Asia, mountainous Latin America)
- **Gastric/Duodenal Cancer**
  - Lynch Syndrome: Every 2-4 years, starting at age 30.
- **Esophageal Varices in Cirrhosis**
  - Cirrhosis with ongoing liver inflammation and no varices: every 2 years
  - Cirrhosis with NO active liver inflammation and no varices: every 3 years
  - Compensated cirrhosis:
    - platelet count >150,000/microL AND liver elastography <20 kPa: no surveillance needed
    - platelet count <150,000/microL or liver elastography ≥20 kPa.
      - Frequency of surveillance
        - Ongoing liver inflammation and small varices without red signs: annual
        - No active liver inflammation and small varices without red signs: every 2 years

\*Spigelman classification for duodenal polyposis:

#### DUODENAL FINDINGS AND MANAGEMENT<sup>a</sup>

- The starting point for management of duodenal findings is the calculation of the modified Spigelman score.<sup>b,c</sup> To calculate the overall Spigelman score, add up the scores for each factor.

Factors	Score			
	0 Points	1 Point	2 Points	3 Points
Number of polyps	0	1–4	5–20	>20
Polyp size, mm	No polyps	1–4	5–10	>10
Histology	No adenomas	Tubular adenomas	Tubulovillous adenoma	Villous adenoma
Dysplasia	No dysplasia	Low grade	—	High grade

[Saurin J, Gutknecht C, Napoleon B, et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 2004; 22:493](#)

### Exclusions and Non-Indicated Uses

The following conditions are considered **INVESTIGATIONAL (NOT MEDICALLY NECESSARY)**, including, but not limited to:

- EGD to rule out celiac disease in:
  - Infertility.
  - GI symptoms with negative serology and no malabsorption indicators.
  - Osteoporosis without malabsorption evidence.
- To evaluate radiographic findings of:
  - Asymptomatic or uncomplicated sliding hiatal hernia.
  - Uncomplicated duodenal ulcer responding to therapy.
  - Deformed duodenal bulb without symptoms or responding to therapy.
- Surveillance of healed benign disease (e.g., esophagitis, gastric/duodenal ulcer).
- Surveillance during repeated dilations of benign strictures unless clinical status changes.

### Prior Authorization Information

#### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if a procedure is performed **inpatient**.

#### Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is <b>not required</b> .
Commercial PPO and Indemnity	Prior authorization is <b>not required</b> .
Medicare HMO Blue <sup>SM</sup>	Prior authorization is <b>not required</b> .
Medicare PPO Blue <sup>SM</sup>	Prior authorization is <b>not required</b> .

### CPT Codes / HCPCS Codes / ICD Codes

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

*The following codes are included below for informational purposes only; this is not an all-inclusive list.*

The above **medical necessity criteria MUST** be met for the following codes to be covered for **Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:**

#### CPT Codes

CPT codes:	Code Description
43200	Esophagoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
43202	Esophagoscopy, flexible, transoral; with biopsy, single or multiple
43231	Esophagoscopy, flexible, transoral; with endoscopic ultrasound examination
43233	Esophagogastroduodenoscopy, flexible, transoral; with dilation of esophagus with balloon 30 mm diameter or larger) (includes fluoroscopic guidance, when performed)
43235	Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)

43237	Esophagogastroduodenoscopy, flexible, transoral; with endoscopic ultrasound examination limited to esophagus
43238	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (included endoscopic ultrasound examination limited to esophagus)
43239	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures)
43242	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum and/or jejunum as appropriate)
43259	Esophagogastroduodenoscopy, flexible, transoral; with endoscopic ultrasound examination, including the esophagus, stomach, and either the duodenum and/or jejunum as appropriate

**The following ICD Diagnosis Codes are considered medically necessary when submitted with the CPT codes above if medical necessity criteria are met:**

### ICD-10 Diagnosis Codes

<b>ICD-10-CM diagnosis codes:</b>	<b>Code Description</b>
C12	Malignant Neoplasm of Pyriform Sinus
C13.0	Malignant Neoplasm of Postcricoid Region
C13.1	Malignant Neoplasm of Aryepiglottic Fold, Hypopharyngeal Aspect
C13.2	Malignant Neoplasm of Posterior Wall of Hypopharynx
C13.8	Malignant Neoplasm of Overlapping Sites of Hypopharynx
C13.9	Malignant Neoplasm of Hypopharynx, Unspecified
C15.3	Malignant Neoplasm of Upper Third of Esophagus
C15.4	Malignant Neoplasm of Middle Third of Esophagus
C15.5	Malignant Neoplasm of Lower Third of Esophagus
C15.8	Malignant Neoplasm of Overlapping Sites of Esophagus
C15.9	Malignant Neoplasm of Esophagus, Unspecified
C16.0	Malignant Neoplasm of Cardia
C16.1	Malignant Neoplasm of Fundus of Stomach
C16.2	Malignant Neoplasm of Body of Stomach
C16.3	Malignant Neoplasm of Pyloric Antrum
C16.4	Malignant Neoplasm of Pylorus
C16.5	Malignant Neoplasm of Lesser Curvature of Stomach, Unspecified
C16.6	Malignant Neoplasm of Greater Curvature of Stomach, Unspecified
C16.8	Malignant Neoplasm of Overlapping Sites of Stomach
C16.9	Malignant Neoplasm of Stomach, Unspecified
C17.0	Malignant Neoplasm of Duodenum
C17.1	Malignant Neoplasm of Jejunum
C17.2	Malignant Neoplasm of Ileum
C17.3	Meckel's Diverticulum, Malignant
C17.8	Malignant Neoplasm of Overlapping Sites of Small Intestine
C17.9	Malignant Neoplasm of Small Intestine, Unspecified
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix

C18.2	Malignant neoplasm of ascending colon
C18.4	Malignant neoplasm of transverse colon
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of colon
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant Neoplasm of Rectosigmoid Junction
C20	Malignant neoplasm of rectum
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C32.0	Malignant Neoplasm of Glottis
C32.1	Malignant Neoplasm of Supraglottis
C32.2	Malignant Neoplasm of Subglottis
C32.3	Malignant Neoplasm of Laryngeal Cartilage
C32.8	Malignant Neoplasm of Overlapping Sites of Larynx
C32.9	Malignant Neoplasm of Larynx, Unspecified
C33	Malignant Neoplasm of Trachea
C78.5	Secondary malignant neoplasm of large intestine and rectum
C78.80	Secondary malignant neoplasm of unspecified digestive organ
C78.89	Secondary malignant neoplasm of other digestive organs
C78.1	Secondary Malignant Neoplasm of Mediastinum
C78.30	Secondary Malignant Neoplasm of Unspecified Respiratory organ
C78.39	Secondary Malignant Neoplasm of Other Respiratory organs
C78.4	Secondary Malignant Neoplasm of Small Intestine
C81.01	Nodular Lymphocyte Predominant Hodgkin Lymphoma, Lymph Nodes of Head, Face, and Neck
C81.02	Nodular Lymphocyte Predominant Hodgkin Lymphoma, Intrathoracic Lymph Nodes
C81.03	Nodular Lymphocyte Predominant Hodgkin Lymphoma, Intra-Abdominal Lymph Nodes
C81.11	Nodular Sclerosis Hodgkin Lymphoma, Lymph Nodes of Head, Face, and Neck
C81.12	Nodular Sclerosis Hodgkin Lymphoma, Intrathoracic Lymph Nodes
C81.13	Nodular Sclerosis Hodgkin Lymphoma, Intra-Abdominal Lymph Nodes
C81.21	Mixed Cellularity Hodgkin Lymphoma, Lymph Nodes of Head, Face, and Neck
C81.22	Mixed Cellularity Hodgkin Lymphoma, Intrathoracic Lymph Nodes
C81.23	Mixed Cellularity Hodgkin Lymphoma, Intra-Abdominal Lymph Nodes
C81.31	Lymphocyte Depleted Hodgkin Lymphoma, Lymph Nodes of Head, Face, and Neck
C81.32	Lymphocyte Depleted Hodgkin Lymphoma, Intrathoracic Lymph Nodes
C81.33	Lymphocyte Depleted Hodgkin Lymphoma, Intra-Abdominal Lymph
C81.41	Lymphocyte-Rich Hodgkin Lymphoma, Lymph Nodes of Head, Face, and Neck
C81.42	Lymphocyte-Rich Hodgkin Lymphoma, Intrathoracic Lymph Nodes
C81.43	Lymphocyte-Rich Hodgkin Lymphoma, Intra-Abdominal Lymph Nodes
C81.71	Other Hodgkin Lymphoma, Lymph Nodes of Head, Face, and Neck
C81.72	Other Hodgkin Lymphoma, Intrathoracic Lymph Nodes
C81.73	Other Hodgkin Lymphoma, Intra-Abdominal Lymph Nodes
C81.91	Hodgkin Lymphoma, Unspecified, Lymph Nodes of Head, Face, and Neck
C81.92	Hodgkin Lymphoma, Unspecified, Intrathoracic Lymph Nodes
C81.93	Hodgkin Lymphoma, Unspecified, Intra-Abdominal Lymph Nodes
C82.01	Follicular Lymphoma Grade I, Lymph Nodes of Head, Face, and Neck
C82.02	Follicular Lymphoma Grade I, Intrathoracic Lymph Nodes

C82.03	Follicular Lymphoma Grade I, Intra-Abdominal Lymph Nodes
C82.11	Follicular Lymphoma Grade II, Lymph Nodes of Head, Face, and Neck
C82.12	Follicular Lymphoma Grade II, Intrathoracic Lymph Nodes
C82.13	Follicular Lymphoma Grade II, Intra-Abdominal Lymph Nodes
C82.21	Follicular Lymphoma Grade III, Unspecified, Lymph Nodes of Head, Face, and Neck
C82.22	Follicular Lymphoma Grade III, Unspecified, Intrathoracic Lymph Nodes
C82.23	Follicular Lymphoma Grade III, Unspecified, Intra-Abdominal Lymph Nodes
C82.31	Follicular Lymphoma Grade III, Lymph Nodes of Head, Face, and Neck
C82.32	Follicular Lymphoma Grade III, Intrathoracic Lymph Nodes
C82.33	Follicular Lymphoma Grade III, Intra-Abdominal Lymph Nodes
C82.51	Diffuse Follicle Center Lymphoma, Lymph Nodes of Head, Face, and Neck
C82.52	Diffuse Follicle Center Lymphoma, Intrathoracic Lymph Nodes
C82.53	Diffuse Follicle Center Lymphoma, Intra-Abdominal Lymph Nodes
C82.61	Cutaneous Follicle Center Lymphoma, Lymph Nodes of Head, Face, and Neck
C82.62	Cutaneous Follicle Center Lymphoma, Intrathoracic Lymph Nodes
C82.63	Cutaneous Follicle Center Lymphoma, Intra-Abdominal Lymph Nodes
C82.81	Other Types of Follicular Lymphoma, Lymph Nodes of Head, Face, and Neck
C82.82	Other Types of Follicular Lymphoma, Intrathoracic Lymph Nodes
C82.83	Other Types of Follicular Lymphoma, Intra-Abdominal Lymph Nodes
C82.91	Follicular Lymphoma, Unspecified, Lymph Nodes of Head, Face, and Neck
C82.92	Follicular Lymphoma, Unspecified, Intrathoracic Lymph Nodes
C82.93	Follicular Lymphoma, Unspecified, Intra-Abdominal Lymph Nodes
C83.01	Small Cell B-Cell Lymphoma, Lymph Nodes of Head, Face, and Neck
C83.02	Small Cell B-Cell Lymphoma, Intrathoracic Lymph Nodes
C83.03	Small Cell B-Cell Lymphoma, Intra-Abdominal Lymph Nodes
C83.11	Mantle Cell Lymphoma, Lymph Nodes of Head, Face, and Neck
C83.12	Mantle Cell Lymphoma, Intrathoracic Lymph Nodes
C83.13	Mantle Cell Lymphoma, Intra-Abdominal Lymph Nodes
C83.31	Diffuse Large B-Cell Lymphoma, Lymph Nodes of Head, Face, and Neck
C83.32	Diffuse Large B-Cell Lymphoma, Intrathoracic Lymph Nodes
C83.33	Diffuse Large B-Cell Lymphoma, Intra-Abdominal Lymph Nodes
C83.51	Lymphoblastic (Diffuse) Lymphoma, Lymph Nodes of Head, Face, and Neck
C83.52	Lymphoblastic (Diffuse) Lymphoma, Intrathoracic Lymph Nodes
C83.53	Lymphoblastic (Diffuse) Lymphoma, Intra-Abdominal Lymph Nodes
C83.71	Burkitt Lymphoma, Lymph Nodes of Head, Face, and Neck
C83.72	Burkitt Lymphoma, Intrathoracic Lymph Nodes
C83.73	Burkitt Lymphoma, Intra-Abdominal Lymph Nodes
C83.81	Other Non-Follicular Lymphoma, Lymph Nodes of Head, Face, and Neck
C83.82	Other Non-Follicular Lymphoma, Intrathoracic Lymph Nodes
C83.83	Other Non-Follicular Lymphoma, Intra-Abdominal Lymph Nodes
C83.91	Non-Follicular (Diffuse) Lymphoma, Unspecified, Lymph Nodes of Head, Face, and Neck
C83.92	Non-Follicular (Diffuse) Lymphoma, Unspecified, Intrathoracic Lymph Nodes
83.93	Non-Follicular (Diffuse) Lymphoma, Unspecified, Intra-Abdominal Lymph

	Nodes
C84.01	Mycosis Fungoides, Lymph Nodes of Head, Face, and Neck
C84.02	Mycosis Fungoides, Intrathoracic Lymph Nodes
C84.03	Mycosis Fungoides, Intra-Abdominal Lymph Nodes
C84.11	Sezary Disease, Lymph Nodes of Head, Face, and Neck
C84.12	Sezary Disease, Intrathoracic Lymph Nodes
C84.13	Sezary Disease, Intra-Abdominal Lymph Nodes
C84.41	Peripheral T-Cell Lymphoma, Not Classified, Lymph Nodes of Head, Face, and Neck
C84.42	Peripheral T-Cell Lymphoma, Not Classified, Intrathoracic Lymph Nodes
C84.43	Peripheral T-Cell Lymphoma, Not Classified, Intra-Abdominal Lymph Nodes
C84.61	Anaplastic Large Cell Lymphoma, Alk-Positive, Lymph Nodes of Head, Face, and Neck
C84.62	Anaplastic Large Cell Lymphoma, Alk-Positive, Intrathoracic Lymph Nodes
C84.63	Anaplastic Large Cell Lymphoma, Alk-Positive, Intra-Abdominal Lymph Nodes
C84.71	Anaplastic Large Cell Lymphoma, Alk-Negative, Lymph Nodes of Head, Face, and Neck
C84.72	Anaplastic Large Cell Lymphoma, Alk-Negative, Intrathoracic Lymph Nodes
C84.73	Anaplastic Large Cell Lymphoma, Alk-Negative, Intra-Abdominal Lymph Nodes
C84.91	Mature T/Nk-Cell Lymphomas, Unspecified, Lymph Nodes of Head, Face, and Neck
C84.92	Mature T/Nk-Cell Lymphomas, Unspecified, Intrathoracic Lymph Nodes
C84.93	Mature T/Nk-Cell Lymphomas, Unspecified, Intra-Abdominal Lymph Nodes
C84.A1	Cutaneous T-Cell Lymphoma, Unspecified Lymph Nodes of Head, Face, and Neck
C84.A2	Cutaneous T-Cell Lymphoma, Unspecified, Intrathoracic Lymph Nodes
C84.A3	Cutaneous T-Cell Lymphoma, Unspecified, Intra-Abdominal Lymph Nodes
C84.Z1	Other Mature T/Nk-Cell Lymphomas, Lymph Nodes of Head, Face, and Neck
C84.Z2	Other Mature T/Nk-Cell Lymphomas, Intrathoracic Lymph Nodes
C84.Z3	Other Mature T/Nk-Cell Lymphomas, Intra-Abdominal Lymph Nodes
C85.11	Unspecified B-Cell Lymphoma, Lymph Nodes of Head, Face, and Neck
C85.12	Unspecified B-Cell Lymphoma, Intrathoracic Lymph Nodes
C85.13	Unspecified B-Cell Lymphoma, Intra-Abdominal Lymph Nodes
C85.21	Mediastinal (Thymic) Large B-Cell Lymphoma, Lymph Nodes of Head, Face, and Neck
C85.22	Mediastinal (Thymic) Large B-Cell Lymphoma, Intrathoracic Lymph Nodes
C85.23	Mediastinal (Thymic) Large B-Cell Lymphoma, Intra-Abdominal Lymph Nodes
C85.81	Other Specified Types of Non-Hodgkin Lymphoma, Lymph Nodes of Head, Face, and Neck
C85.82	Other Specified Types of Non-Hodgkin Lymphoma, Intrathoracic Lymph Nodes
C85.83	Other Specified Types of Non-Hodgkin Lymphoma, Intra-Abdominal Lymph Nodes
C85.91	Non-Hodgkin Lymphoma, Unspecified, Lymph Nodes of Head, Face, and



	Neck
C85.92	Non-Hodgkin Lymphoma, Unspecified, Intrathoracic Lymph Nodes
C85.93	Non-Hodgkin Lymphoma, Unspecified, Intra-Abdominal Lymph Nodes
C86.0	Extranodal Nk/T-Cell Lymphoma, Nasal Type
C86.2	Enteropathy-Type (Intestinal) T-Cell Lymphoma
C86.3	Subcutaneous Panniculitis-Like T-Cell Lymphoma
C86.4	Blastic Nk-Cell Lymphoma
C88.4	Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue [Malt-Lymphoma]
C91.40	Hairy Cell Leukemia Not Having Achieved Remission
C91.41	Hairy Cell Leukemia, In Remission
C91.42	Hairy Cell Leukemia, In Relapse
C96.0	Multifocal and Multisystemic (Disseminated) Langerhans-Cell Histiocytosis
C96.2	Malignant mast cell tumor [confirmation and specific histological diagnosis of radiologically demonstrated lesions]
C96.20	Malignant mast cell neoplasm, unspecified
C96.21	Aggressive systemic mastocytosis
C96.22	Mast cell sarcoma
C96.29	Other malignant mast cell neoplasm
C96.9	Malignant Neoplasm of Lymphoid, Hematopoietic and Related Tissue, Unspecified
C96.A	Histiocytic Sarcoma
C96.Z	Other Specified Malignant Neoplasms of Lymphoid, Hematopoietic and Related Tissue
D00.1	Carcinoma In Situ of Esophagus
D12.0	Benign Neoplasm of Cecum
D12.1	Benign Neoplasm of Appendix
D12.2	Benign Neoplasm of Ascending Colon
D12.3	Benign Neoplasm of Transverse Colon
D12.4	Benign Neoplasm of Descending Colon
D12.5	Benign Neoplasm of Sigmoid Colon
D12.6	Benign Neoplasm of Colon, Unspecified
D13.0	Benign Neoplasm of Esophagus
D13.1	Benign Neoplasm of Stomach
D13.2	Benign Neoplasm of Duodenum
D13.30	Benign Neoplasm of Unspecified Part of Small Intestine
D13.39	Benign Neoplasm of Other Parts of Small Intestine
D13.91	Familial adenomatous polyposis
D37.8	Neoplasm of Uncertain Behavior of Other Specified Digestive organs
D37.9	Neoplasm of Uncertain Behavior of Digestive organ, Unspecified
D50.0	Iron Deficiency Anemia Secondary To Blood Loss (Chronic)
D50.1	Sideropenic Dysphagia
D50.8	Other Iron Deficiency Anemias
D50.9	Iron Deficiency Anemia, Unspecified
D51.0	Vitamin B12 Deficiency Anemia Due To Intrinsic Factor Deficiency
D62.0	Acute Posthemorrhagic Anemia
D89.810	Acute Graft-Versus-Host Disease
D89.811	Chronic Graft-Versus-Host Disease
D89.812	Acute On Chronic Graft-Versus-Host Disease
D89.813	Graft-Versus-Host Disease, Unspecified

E61.1	Iron deficiency
I69.091	Dysphagia Following Nontraumatic Subarachnoid Hemorrhage
I69.191	Dysphagia Following Nontraumatic Intracerebral Hemorrhage
I69.291	Dysphagia Following Other Nontraumatic Intracranial Hemorrhage
I69.391	Dysphagia Following Cerebral Infarction
I69.891	Dysphagia Following Other Cerebrovascular Disease
I69.991	Dysphagia Following Unspecified Cerebrovascular Disease
I85.00	Esophageal Varices without Bleeding
I85.01	Esophageal Varices with Bleeding
I85.10	Secondary Esophageal Varices without Bleeding
I85.11	Secondary Esophageal Varices with Bleeding
I86.4	Gastric varices
J86.0	Pyothorax with Fistula
K20.0	Eosinophilic Esophagitis
K20.80	Other esophagitis without bleeding
K20.81	Other esophagitis with bleeding
K20.90	Esophagitis, unspecified without bleeding
K20.91	Esophagitis, unspecified with bleeding
K21.00	Gastro-esophageal reflux disease with esophagitis, without bleeding
K21.01	Gastro-esophageal reflux disease with esophagitis, with bleeding
K21.9	Gastro-esophageal reflux disease without esophagitis
K22.0	Achalasia of Cardia
K22.10	Ulcer of Esophagus without Bleeding
K22.11	Ulcer of Esophagus with Bleeding
K22.2	Esophageal Obstruction
K22.3	Perforation of Esophagus
K22.4	Dyskinesia of Esophagus
K22.5	Diverticulum of Esophagus, Acquired
K22.6	Gastro-Esophageal Laceration-Hemorrhage Syndrome
K22.70	Barrett's Esophagus without Dysplasia
K22.710	Barrett's Esophagus with Low Grade Dysplasia
K22.711	Barrett's Esophagus with High Grade Dysplasia
K22.719	Barrett's Esophagus with Dysplasia, Unspecified
K22.89	Other Specified Diseases of Esophagus
K25.0	Acute Gastric Ulcer with Hemorrhage
K25.1	Acute Gastric Ulcer with Perforation
K25.2	Acute Gastric Ulcer with Both Hemorrhage and Perforation
K25.3	Acute Gastric Ulcer without Hemorrhage or Perforation
K25.4	Chronic or Unspecified Gastric Ulcer with Hemorrhage
K25.5	Chronic or Unspecified Gastric Ulcer with Perforation
K25.6	Chronic or Unspecified Gastric Ulcer with Both Hemorrhage and Perforation
K25.7	Chronic Gastric Ulcer without Hemorrhage or Perforation
K25.9	Gastric Ulcer, Unspecified as Acute or Chronic, without Hemorrhage or Perforation
K26.0	Acute Duodenal Ulcer with Hemorrhage
K26.1	Acute Duodenal Ulcer with Perforation
K26.2	Acute Duodenal Ulcer with Both Hemorrhage and Perforation
K26.3	Acute Duodenal Ulcer without Hemorrhage or Perforation
K26.4	Chronic or Unspecified Duodenal Ulcer with Hemorrhage
K26.5	Chronic or Unspecified Duodenal Ulcer with Perforation

K26.6	Chronic or Unspecified Duodenal Ulcer with Both Hemorrhage and Perforation
K26.7	Chronic Duodenal Ulcer without Hemorrhage or Perforation
K26.9	Duodenal Ulcer, Unspecified as Acute or Chronic, without Hemorrhage or Perforation
K27.0	Acute Peptic Ulcer, Site Unspecified, with Hemorrhage
K27.1	Acute Peptic Ulcer, Site Unspecified, with Perforation
K27.2	Acute Peptic Ulcer, Site Unspecified, with Both Hemorrhage and Perforation
K27.3	Acute Peptic Ulcer, Site Unspecified, without Hemorrhage or Perforation
K27.4	Chronic or Unspecified Peptic Ulcer, Site Unspecified, with Hemorrhage
K27.5	Chronic or Unspecified Peptic Ulcer, Site Unspecified, with Perforation
K27.6	Chronic or Unspecified Peptic Ulcer, Site Unspecified, with Both Hemorrhage and Perforation
K27.7	Chronic Peptic Ulcer, Site Unspecified, without Hemorrhage or Perforation
K27.9	Peptic Ulcer, Site Unspecified, Unspecified as Acute or Chronic, without Hemorrhage or Perforation
K28.0	Acute Gastrojejunal Ulcer with Hemorrhage
K28.1	Acute Gastrojejunal Ulcer with Perforation
K28.2	Acute Gastrojejunal Ulcer with Both Hemorrhage and Perforation
K28.3	Acute Gastrojejunal Ulcer without Hemorrhage or Perforation
K28.4	Chronic or Unspecified Gastrojejunal Ulcer with Hemorrhage
K28.5	Chronic or Unspecified Gastrojejunal Ulcer with Perforation
K28.6	Chronic or Unspecified Gastrojejunal Ulcer with Both Hemorrhage and Perforation
K28.7	Chronic Gastrojejunal Ulcer without Hemorrhage or Perforation
K28.9	Gastrojejunal Ulcer, Unspecified as Acute or Chronic, without Hemorrhage or Perforation
K29.00	Acute Gastritis without Bleeding
K29.01	Acute Gastritis with Bleeding
K29.20	Alcoholic Gastritis without Bleeding
K29.21	Alcoholic Gastritis with Bleeding
K29.30	Chronic Superficial Gastritis without Bleeding
K29.31	Chronic Superficial Gastritis with Bleeding
K29.40	Chronic Atrophic Gastritis without Bleeding
K29.41	Chronic Atrophic Gastritis with Bleeding
K29.50	Unspecified Chronic Gastritis without Bleeding
K29.51	Unspecified Chronic Gastritis with Bleeding
K29.60	Other Gastritis without Bleeding
K29.61	Other Gastritis with Bleeding
K29.70	Gastritis, Unspecified, without Bleeding
K29.71	Gastritis, Unspecified, with Bleeding
K29.80	Duodenitis without Bleeding
K29.81	Duodenitis with Bleeding
K29.90	Gastroduodenitis, Unspecified, without Bleeding
K29.91	Gastroduodenitis, Unspecified, with Bleeding
K30	Functional Dyspepsia
K31.0	Acute dilatation of stomach
K31.1	Adult hypertrophic pyloric stenosis
K31.2	Hourglass stricture and stenosis of stomach
K31.3	Pylorospasm, not elsewhere classified

K31.4	Gastric diverticulum
K31.5	Obstruction of duodenum
K31.6	Fistula of stomach and duodenum
K31.7	Polyp of Stomach and Duodenum
K31.811	Angiodysplasia of stomach and duodenum with bleeding
K31.819	Angiodysplasia of stomach and duodenum without bleeding
K31.82	Dieulafoy lesion (hemorrhagic) of stomach and duodenum
K31.83	Achlorhydria
K31.84	Gastroparesis
K31.89	Other diseases of stomach and duodenum
K31.9	Disease of stomach and duodenum, unspecified
K31.A0	Gastric intestinal metaplasia, unspecified
K31.A11	Gastric intestinal metaplasia without dysplasia, involving the antrum
K31.A12	Gastric intestinal metaplasia without dysplasia, involving the body (corpus)
K31.A13	Gastric intestinal metaplasia without dysplasia, involving the fundus
K31.A14	Gastric intestinal metaplasia without dysplasia, involving the cardia
K31.A15	Gastric intestinal metaplasia without dysplasia, involving multiple sites
K31.A19	Gastric intestinal metaplasia without dysplasia, unspecified site
K31.A21	Gastric intestinal metaplasia with low grade dysplasia
K31.A22	Gastric intestinal metaplasia with high grade dysplasia
K31.A29	Gastric intestinal metaplasia with dysplasia, unspecified
K44.0	Diaphragmatic Hernia with Obstruction, without Gangrene
K50.00	Crohn's Disease of Small Intestine without Complications
K50.011	Crohn's Disease of Small Intestine with Rectal Bleeding
K50.012	Crohn's Disease of Small Intestine with Intestinal Obstruction
K50.013	Crohn's Disease of Small Intestine with Fistula
K50.014	Crohn's Disease of Small Intestine with Abscess
K50.018	Crohn's Disease of Small Intestine with Other Complication
K50.019	Crohn's Disease of Small Intestine with Unspecified Complications
K50.11	Crohn's disease of large intestine with complications
K50.111	Crohn's disease of large intestine with rectal bleeding
K50.112	Crohn's disease of large intestine with intestinal obstruction
K50.113	Crohn's disease of large intestine with fistula
K50.114	Crohn's disease of large intestine with abscess
K50.118	Crohn's disease of large intestine with other complication
K50.119	Crohn's disease of large intestine with unspecified complications
K50.8	Crohn's disease of both small and large intestine
K50.80	Crohn's disease of both small and large intestine without complications
K50.81	Crohn's disease of both small and large intestine with complications
K50.811	Crohn's disease of both small and large intestine with rectal bleeding
K50.812	Crohn's disease of both small and large intestine with intestinal obstruction
K50.813	Crohn's disease of both small and large intestine with fistula
K50.814	Crohn's disease of both small and large intestine with abscess
K50.818	Crohn's disease of both small and large intestine with other complication
K50.819	Crohn's disease of both small and large intestine with unspecified complications
K50.9	Crohn's disease, unspecified
K50.90	Crohn's disease, unspecified, without complications
K50.91	Crohn's disease, unspecified, with complications
K50.911	Crohn's disease, unspecified, with rectal bleeding
K50.912	Crohn's disease, unspecified, with intestinal obstruction

K50.913	Crohn's disease, unspecified, with fistula
K50.914	Crohn's disease, unspecified, with abscess
K50.918	Crohn's disease, unspecified, with other complication
K50.919	Crohn's disease, unspecified, with unspecified complications
K51.00	Ulcerative (Chronic) Pancolitis without Complications
K51.011	Ulcerative (Chronic) Pancolitis with Rectal Bleeding
K51.012	Ulcerative (Chronic) Pancolitis with Intestinal Obstruction
K51.013	Ulcerative (Chronic) Pancolitis with Fistula
K51.014	Ulcerative (Chronic) Pancolitis with Abscess
K51.018	Ulcerative (Chronic) Pancolitis with Other Complication
K51.019	Ulcerative (Chronic) Pancolitis with Unspecified Complications
K52.0	Gastroenteritis and colitis due to radiation
K52.1	Toxic gastroenteritis and colitis
K52.21	Food protein-induced enterocolitis syndrome
K52.22	Food protein-induced enteropathy
K52.29	Other allergic and dietetic gastroenteritis and colitis
K52.81	Eosinophilic gastritis or gastroenteritis
K52.89	Other specified noninfective gastroenteritis and colitis
K52.9	Noninfective gastroenteritis and colitis, unspecified
K58.0	Irritable Bowel Syndrome with Diarrhea
K58.1	Irritable Bowel Syndrome with Constipation
K58.2	Mixed Irritable Bowel Syndrome
K58.8	Other Irritable Bowel Syndrome
K58.9	Irritable Bowel Syndrome without Diarrhea
K63.5	Polyp of Colon
K70.2	Alcoholic Fibrosis and Sclerosis of Liver
K70.30	Alcoholic Cirrhosis of Liver without Ascites
K70.31	Alcoholic Cirrhosis of Liver with Ascites
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver
K74.00	Hepatic fibrosis, unspecified
K74.01	Hepatic fibrosis, early fibrosis
K74.02	Hepatic fibrosis, advanced fibrosis
K74.3	Primary Biliary Cirrhosis
K74.4	Secondary Biliary Cirrhosis
K74.5	Biliary Cirrhosis, Unspecified
K74.60	Unspecified Cirrhosis of Liver
K74.69	Other Cirrhosis of Liver
K76.6	Portal Hypertension
K86.2	Cyst of pancreas
K90.0	Celiac disease
K92.0	Hematemesis
K92.1	Melena
K92.2	Gastrointestinal Hemorrhage, Unspecified
K94.30	Esophagostomy Complications, Unspecified
K94.31	Esophagostomy Hemorrhage
K94.33	Esophagostomy Infection
K94.39	Esophagostomy Malfunction
Q26.5	Other Complications of Esophagostomy
Q26.6	Portal Vein-Hepatic Artery Fistula
Q27.33	Arteriovenous Malformation of Digestive System Vessel
Q27.8	Other Specified Congenital Malformations of Peripheral Vascular System

Q39.0	Atresia of Esophagus without Fistula
Q39.1	Atresia of Esophagus with Tracheo-Esophageal Fistula
Q39.2	Congenital Tracheo-Esophageal Fistula without Atresia
Q39.3	Congenital Stenosis and Stricture of Esophagus
Q39.4	Esophageal Web
Q39.5	Congenital Dilatation of Esophagus
Q39.6	Congenital Diverticulum of Esophagus
Q39.8	Other Congenital Malformations of Esophagus
Q39.9	Congenital Malformation of Esophagus, Unspecified
Q40.2	Other Specified Congenital Malformations of Stomach
Q40.3	Congenital Malformation of Stomach, Unspecified
Q43.5	Ectopic anus
Q43.6	Congenital fistula of rectum and anus
Q43.7	Persistent cloaca
Q43.8	Other specified congenital malformations of intestine
Q43.9	Congenital malformation of intestine, unspecified
Q82.8	Other specified congenital malformations of skin
R10.0	Acute abdomen
R10.10	Upper abdominal pain, unspecified
R10.11	Right Upper Quadrant Pain
R10.12	Left Upper Quadrant Pain
R10.13	Epigastric pain
R10.30	Lower abdominal pain, unspecified
R10.31	Right lower quadrant pain
R10.32	Left lower quadrant pain
R10.33	Periumbilical pain
R10.84	Generalized abdominal pain
R11.0	Nausea with vomiting
R11.10	Vomiting, unspecified
R11.11	Vomiting without nausea
R11.12	Projectile vomiting
R11.13	Vomiting of fecal matter
R11.14	Bilious vomiting
R11.2	Nausea with vomiting, unspecified
R13.10	Dysphagia, Unspecified
R13.11	Dysphagia, oral Phase
R13.12	Dysphagia, oropharyngeal Phase
R13.13	Dysphagia, Pharyngeal Phase
R13.14	Dysphagia, Pharyngoesophageal Phase
R13.19	Other Dysphagia
R63.4	Abnormal weight loss
R93.3	Abnormal Findings on Diagnostic Imaging of Other Parts of Digestive Tract
R93.5	Abnormal Findings on Diagnostic Imaging of Other Abdominal Regions, Including Retroperitoneum
S21.301A	Unspecified Open Wound of Right Front Wall of Thorax with Penetration into Thoracic Cavity, Initial Encounter
S21.301D	Unspecified Open Wound of Right Front Wall of Thorax with Penetration into Thoracic Cavity, Subsequent Encounter
S21.301S	Unspecified Open Wound of Right Front Wall of Thorax with Penetration into Thoracic Cavity, Sequela

S21.302A	Unspecified Open Wound of Left Front Wall of Thorax with Penetration Into Thoracic Cavity, Initial Encounter
S21.302D	Unspecified Open Wound of Left Front Wall of Thorax with Penetration into Thoracic Cavity, Subsequent Encounter
S21.302S	Unspecified Open Wound of Left Front Wall of Thorax with Penetration Into Thoracic Cavity, Sequela
S21.309A	Unspecified Open Wound of Unspecified Front Wall of Thorax with Penetration Into Thoracic Cavity, Initial Encounter
S21.309D	Unspecified Open Wound of Unspecified Front Wall of Thorax with Penetration Into Thoracic Cavity, Subsequent Encounter
S21.309S	Unspecified Open Wound of Unspecified Front Wall of Thorax with Penetration Into Thoracic Cavity, Sequela
S27.812A	Contusion of Esophagus (Thoracic Part), Initial Encounter
S27.812D	Contusion of Esophagus (Thoracic Part), Subsequent Encounter
S27.812S	Contusion of Esophagus (Thoracic Part), Sequela
S27.813A	Laceration of Esophagus (Thoracic Part), Initial Encounter
S27.813D	Laceration of Esophagus (Thoracic Part), Subsequent Encounter
S27.813S	Laceration of Esophagus (Thoracic Part), Sequela
S27.818A	Other Injury of Esophagus (Thoracic Part), Initial Encounter
S27.818D	Other Injury of Esophagus (Thoracic Part), Subsequent Encounter
S27.818S	Other Injury of Esophagus (Thoracic Part), Sequela
S27.819A	Unspecified Injury of Esophagus (Thoracic Part), Initial Encounter
S27.819D	Unspecified Injury of Esophagus (Thoracic Part), Subsequent Encounter
S27.819S	Unspecified Injury of Esophagus (Thoracic Part), Sequela
T18.100A	Unspecified Foreign Body in Esophagus Causing Compression of Trachea, Initial Encounter
T18.100D	Unspecified Foreign Body in Esophagus Causing Compression of Trachea, Subsequent Encounter
T18.100S	Unspecified Foreign Body in Esophagus Causing Compression of Trachea, Sequela
T18.108A	Unspecified Foreign Body in Esophagus Causing Other Injury, Initial Encounter
T18.108D	Unspecified Foreign Body in Esophagus Causing Other Injury, Subsequent Encounter
T18.108S	Unspecified Foreign Body in Esophagus Causing Other Injury, Sequela
T18.110A	Gastric Contents in Esophagus Causing Compression of Trachea, Initial Encounter
T18.110D	Gastric Contents in Esophagus Causing Compression of Trachea, Subsequent Encounter
T18.110S	Gastric Contents in Esophagus Causing Compression of Trachea, Sequela
T18.118A	Gastric Contents in Esophagus Causing Other Injury, Initial Encounter
T18.118D	Gastric Contents in Esophagus Causing Other Injury, Subsequent Encounter
T18.118S	Gastric Contents in Esophagus Causing Other Injury, Sequela
T18.120A	Food In Esophagus Causing Compression of Trachea, Initial Encounter
T18.120D	Food In Esophagus Causing Compression of Trachea, Subsequent Encounter
T18.120S	Food In Esophagus Causing Compression of Trachea, Sequela
T18.128A	Food In Esophagus Causing Other Injury, Initial Encounter
T18.128D	Food In Esophagus Causing Other Injury, Subsequent Encounter
T18.128S	Food In Esophagus Causing Other Injury, Sequela
T18.190A	Other Foreign Object in Esophagus Causing Compression of Trachea, Initial Encounter
T18.190D	Other Foreign Object in Esophagus Causing Compression of Trachea, Subsequent Encounter
T18.190S	Other Foreign Object in Esophagus Causing Compression of Trachea, Sequela
T18.198A	Other Foreign Object in Esophagus Causing Other Injury, Initial Encounter
T18.198D	Other Foreign Object in Esophagus Causing Other Injury, Subsequent Encounter
T18.198S	Other Foreign Object in Esophagus Causing Other Injury, Sequela

T18.2XXA	Foreign Body in Stomach, Initial Encounter
T18.2XXD	Foreign Body in Stomach, Subsequent Encounter
T18.2XXS	Foreign Body in Stomach, Sequela
T18.8XXA	Foreign Body in Other Parts of Alimentary Tract, Initial Encounter
T18.8XXD	Foreign Body in Other Parts of Alimentary Tract, Subsequent Encounter
T18.8XXS	Foreign Body in Other Parts of Alimentary Tract, Sequela
T18.9XXA	Foreign Body of Alimentary Tract, Part Unspecified, Initial Encounter
T18.9XXD	Foreign Body of Alimentary Tract, Part Unspecified, Subsequent Encounter
T18.9XXS	Foreign Body of Alimentary Tract, Part Unspecified, Sequela
T28.1XXA	Burn of Esophagus, Initial Encounter
T28.1XXD	Burn of Esophagus, Subsequent Encounter
T28.1XXS	Burn of Esophagus, Sequela
T28.6XXA	Corrosion of Esophagus, Initial Encounter
T28.6XXD	Corrosion of Esophagus, Subsequent Encounter
T28.6XXS	Corrosion of Esophagus, Sequela
T54.0X1A	Toxic Effect of Phenol and Phenol Homologues, Accidental (Unintentional), Initial Encounter
T54.0X1D	Toxic Effect of Phenol and Phenol Homologues, Accidental (Unintentional), Subsequent Encounter
T54.0X1S	Toxic Effect of Phenol and Phenol Homologues, Accidental (Unintentional), Sequela
T54.0X2A	Toxic Effect of Phenol and Phenol Homologues, Intentional Self-Harm, Initial Encounter
T54.0X2D	Toxic Effect of Phenol and Phenol Homologues, Intentional Self-Harm, Subsequent Encounter
T54.0X2S	Toxic Effect of Phenol and Phenol Homologues, Intentional Self-Harm, Sequela
T54.0X3A	Toxic Effect of Phenol and Phenol Homologues, Assault, Initial Encounter
T54.0X3D	Toxic Effect of Phenol and Phenol Homologues, Assault, Subsequent Encounter
T54.0X3S	Toxic Effect of Phenol and Phenol Homologues, Assault, Sequela
T54.0X4A	Toxic Effect of Phenol and Phenol Homologues, Undetermined, Initial Encounter
T54.0X4D	Toxic Effect of Phenol and Phenol Homologues, Undetermined, Subsequent Encounter
T54.0X4S	Toxic Effect of Phenol and Phenol Homologues, Undetermined, Sequela
T54.1X1A	Toxic Effect of Other Corrosive organic Compounds, Accidental (Unintentional), Initial Encounter
T54.1X1D	Toxic Effect of Other Corrosive organic Compounds, Accidental (Unintentional), Subsequent Encounter
T54.1X1S	Toxic Effect of Other Corrosive organic Compounds, Accidental (Unintentional), Sequela
T54.1X2A	Toxic Effect of Other Corrosive organic Compounds, Intentional Self- Harm, Initial Encounter
T54.1X2D	Toxic Effect of Other Corrosive organic Compounds, Intentional Self- Harm, Subsequent Encounter
T54.1X2S	Toxic Effect of Other Corrosive organic Compounds, Intentional Self- Harm, Sequela
T54.1X3A	Toxic Effect of Other Corrosive organic Compounds, Assault, Initial Encounter
T54.1X3D	Toxic Effect of Other Corrosive organic Compounds, Assault, Subsequent Encounter
T54.1X3S	Toxic Effect of Other Corrosive organic Compounds, Assault, Sequela
T54.1X4A	Toxic Effect of Other Corrosive organic Compounds, Undetermined, Initial Encounter
T54.1X4D	Toxic Effect of Other Corrosive organic Compounds, Undetermined, Subsequent Encounter
T54.1X4S	Toxic Effect of Other Corrosive organic Compounds, Undetermined, Sequela
T54.2X1A	Toxic Effect of Corrosive Acids and Acid-Like Substances, Accidental (Unintentional), Initial Encounter
T54.2X1D	Toxic Effect of Corrosive Acids and Acid-Like Substances, Accidental (Unintentional), Subsequent Encounter



T54.2X1S	Toxic Effect of Corrosive Acids and Acid-Like Substances, Accidental (Unintentional), Sequela
T54.2X2A	Toxic Effect of Corrosive Acids and Acid-Like Substances, Intentional Self- Harm, Initial Encounter
T54.2X2D	Toxic Effect of Corrosive Acids and Acid-Like Substances, Intentional Self- Harm, Subsequent Encounter
T54.2X2S	Toxic Effect of Corrosive Acids and Acid-Like Substances, Intentional Self- Harm, Sequela
T54.2X3A	Toxic Effect of Corrosive Acids and Acid-Like Substances, Assault, Initial Encounter
T54.2X3D	Toxic Effect of Corrosive Acids and Acid-Like Substances, Assault, Subsequent Encounter
T54.2X3S	Toxic Effect of Corrosive Acids and Acid-Like Substances, Assault, Sequela
T54.2X4A	Toxic Effect of Corrosive Acids and Acid-Like Substances, Undetermined, Initial Encounter
T54.2X4D	Toxic Effect of Corrosive Acids and Acid-Like Substances, Undetermined, Subsequent Encounter
T54.2X4S	Toxic Effect of Corrosive Acids and Acid-Like Substances, Undetermined, Sequela
T54.3X1A	Toxic Effect of Corrosive Alkalis and Alkali-Like Substances, Accidental (Unintentional), Initial Encounter
T54.3X1D	Toxic Effect of Corrosive Alkalis and Alkali-Like Substances, Accidental (Unintentional), Subsequent Encounter
T54.3X1S	Toxic Effect of Corrosive Alkalis and Alkali-Like Substances, Accidental (Unintentional), Sequela
T54.3X2A	Toxic Effect of Corrosive Alkalis and Alkali-Like Substances, Intentional Self-Harm, Initial Encounter
T54.3X2D	Toxic Effect of Corrosive Alkalis and Alkali-Like Substances, Intentional Self-Harm, Subsequent Encounter
T54.3X2S	Toxic Effect of Corrosive Alkalis and Alkali-Like Substances, Intentional Self-Harm, Sequela
T54.3X3A	Toxic Effect of Corrosive Alkalis and Alkali-Like Substances, Assault, Initial Encounter
T54.3X3D	Toxic Effect of Corrosive Alkalis and Alkali-Like Substances, Assault, Subsequent Encounter
T54.3X3S	Toxic Effect of Corrosive Alkalis and Alkali-Like Substances, Assault, Sequela
T54.3X4A	Toxic Effect of Corrosive Alkalis and Alkali-Like Substances, Undetermined, Initial Encounter
T54.3X4D	Toxic Effect of Corrosive Alkalis and Alkali-Like Substances, Undetermined, Subsequent Encounter
T54.3X4S	Toxic Effect of Corrosive Alkalis and Alkali-Like Substances, Undetermined, Sequela
T54.91XA	Toxic Effect of Unspecified Corrosive Substance, Accidental (Unintentional), Initial Encounter
T54.91XD	Toxic Effect of Unspecified Corrosive Substance, Accidental (Unintentional), Subsequent Encounter
T54.91XS	Toxic Effect of Unspecified Corrosive Substance, Accidental (Unintentional), Sequela
T54.92XA	Toxic Effect of Unspecified Corrosive Substance, Intentional Self-Harm, Initial Encounter
T54.92XD	Toxic Effect of Unspecified Corrosive Substance, Intentional Self-Harm, Subsequent Encounter
T54.92xS	Toxic Effect of Unspecified Corrosive Substance, Intentional Self-Harm, Sequela
T54.93xA	Toxic Effect of Unspecified Corrosive Substance, Assault, Initial Encounter
T54.93XD	Toxic Effect of Unspecified Corrosive Substance, Assault, Subsequent Encounter
T54.93XS	Toxic Effect of Unspecified Corrosive Substance, Assault, Sequela
T54.94xA	Toxic Effect of Unspecified Corrosive Substance, Undetermined, Initial Encounter
T54.94XD	Toxic Effect of Unspecified Corrosive Substance, Undetermined, Subsequent Encounter
T54.94xS	Toxic Effect of Unspecified Corrosive Substance, Undetermined, Sequela

T57.1X1A	Toxic Effect of Phosphorus and Its Compounds, Accidental (Unintentional), Initial Encounter
T57.1X1D	Toxic Effect of Phosphorus and Its Compounds, Accidental (Unintentional), Subsequent Encounter
T57.1X1S	Toxic Effect of Phosphorus and Its Compounds, Accidental (Unintentional), Sequela
T57.1X2A	Toxic Effect of Phosphorus and Its Compounds, Intentional Self-Harm, Initial Encounter
T57.1X2D	Toxic Effect of Phosphorus and Its Compounds, Intentional Self-Harm, Subsequent Encounter
T57.1X2S	Toxic Effect of Phosphorus and Its Compounds, Intentional Self-Harm, Sequela
T57.1X3A	Toxic Effect of Phosphorus and Its Compounds, Assault, Initial Encounter
T57.1X3D	Toxic Effect of Phosphorus and Its Compounds, Assault, Subsequent Encounter
T57.1X3S	Toxic Effect of Phosphorus and Its Compounds, Assault, Sequela
T57.1X4A	Toxic Effect of Phosphorus and Its Compounds, Undetermined, Initial Encounter
T57.1X4D	Toxic Effect of Phosphorus and Its Compounds, Undetermined, Subsequent Encounter
T57.1X4S	Toxic Effect of Phosphorus and Its Compounds, Undetermined, Sequela
Z15.09	Genetic Susceptibility to Other Malignant Neoplasm
Z83.72	Family history of familial adenomatous polyposis
Z85.020	Personal History of Malignant Carcinoid Tumor of Stomach
Z85.028	Personal History of Other Malignant Neoplasm of Stomach
Z86.010	Personal History of Colonic Polyps
Z86.19	Personal History of Other Infectious and Parasitic Diseases
Z87.11	Personal History of Peptic Ulcer Disease
Z87.19	Personal History of Other Diseases of The Digestive System

## Description

Upper GI series and upper endoscopy/esophagogastroduodenoscopy (EGD) both examine the upper GI tract; however the procedures are very different.

### Upper GI series

An upper gastrointestinal (GI) series, sometimes called a [barium swallow](#), is an X-ray procedure that uses a contrast agent (barium) to visualize the upper part of the digestive system, including the esophagus, stomach, and the first part of the small intestine (duodenum).

### Upper GI endoscopy or EGD

Uses a flexible fiber-optic scope with a light and camera to examine the upper part of the GI system. The scope is inserted through the mouth into the upper GI tract to view the esophagus, stomach, and duodenum through the camera.

EGD is usually performed to evaluate symptoms of persistent upper abdominal pain, nausea, vomiting, and difficulty swallowing or bleeding from the upper GI tract. This procedure is more accurate than x-ray imaging for detecting inflammation, ulcers, or tumors of the esophagus, stomach and duodenum and can detect early cancer, as well as distinguish between benign and malignant conditions when biopsies of suspicious areas are obtained.

EGD is indicated in the screening and diagnostic evaluation of signs and symptoms of a wide variety of GI disorders as well as for therapeutic interventions. EGD is indicated for the diagnosis of conditions such as, but not limited to, gastritis, celiac disease, esophagitis, esophageal varices, GERD, and ulcers. EGD may also be indicated for the investigation upper gastrointestinal symptoms. Abnormal imaging or caustic ingestion may also indicate the need for EGD.

## Summary

The quality of medical evidence concerning the safety and efficacy of EGD is lacking for the majority of the most common uses of the technology. In an effort to guide clinical practice and to provide safe recommendations in the use of EGD, the American Society for Gastrointestinal Endoscopy (ASGE), the American Gastroenterological Association (AGA), and the American College of Gastroenterology (ACG) have established practice guidelines based largely on consensus within these respective specialty medical societies.

In 2012, the ASGE published a broad guideline on appropriate use of GI Endoscopy. The guideline contains several position statements based on a critical review of the available data as well as expert consensus. The ASGE also published the following indication-specific guidelines including Endoscopy in Gastroduodenal Obstruction and Gastroparesis (2011); Endoscopy in Barrett's Esophagus and other Premalignant Conditions of the Esophagus (2012); Endoscopy in Dyspepsia (2015); Endoscopy in the Management of Benign and Malignant Gastroduodenal Obstruction (2021). The indication-specific guidelines also contain recommendations based on consensus and a review of the literature. The ACG has also published indication-specific clinical practice guidelines on the use of endoscopy in commonly encountered clinical scenarios, such as Diagnosis and Management of Barrett's Esophagus (Shaheen 2022), Gastroparesis (Camilleri, 2022), and Diagnosis and Management of Achalasia (Vaezi, 2020).

Medically necessary indications are largely based on ASGE, ACG and AGA recommendations that are graded as moderate to high quality.

## Policy History

Date	Action
8/2025	New policy describing medically necessary and investigational indications. Effective 8/1/2025.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. American Gastroenterological Association; Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. *Gastroenterology*. 2011; 140(3):1084-1091.
2. ASGE Standards of Practice Committee, Banerjee S, Cash BD, Dominitz JA, et al. The role of endoscopy in the management of patients with peptic ulcer disease. *Gastrointest Endosc*. 2010; 71(4):663-668.
3. ASGE Standards of Practice Committee, Early, DS., Ben-Menachem, T., et al. Appropriate use of GI endoscopy. *Gastrointest Endosc*. 2012; 75:1127.
4. ASGE Standards of Practice Committee, Evans JA, Chandrasekhara V, Chathadi KV, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. *Gastrointest Endosc*. 2015; 82(1):1-8.
5. ASGE Standards of Practice Committee, Jue TL, Storm AC, Naveed M, et al. ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction. *Gastrointest Endosc*. 2021; 93(2):309-322.e4.
6. ASGE Standards of Practice Committee, Shen, B., Khan, K., et al. The role of endoscopy in the management of patients with diarrhea. *Gastrointest Endosc*. 2010; 71(6):887-892.
7. ASGE Standards of Practice Committee; Early DS, Ben-Menachem T, Decker GA, et al. Appropriate use of GI endoscopy. *Gastrointest Endosc*. 2012; 75(6):1127-1131.

8. ASGE Standards of Practice Committee; Evans JA, Early DS, Fukami N, et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. *Gastrointest Endosc.* 2012; 76(6):1087-1094.
9. ASGE Standards of Practice Committee; Evans JA, Muthusamy VR, Acosta RD, et al. The role of endoscopy in the bariatric surgery patient. *Surg Obes Relat Dis.* 2015; 11(3):507-517.
10. ASGE Standards of Practice Committee; Fujii-Lau LL, Thosani NC, Al-Haddad M, et al. The role of endoscopy in the diagnosis of malignancy in biliary strictures of undetermined etiology: summary and recommendations. *Gastrointest Endosc.* 2023; 98:685-693.
11. ASGE Standards of Practice Committee; Fukami N, Anderson MA, Khan K, et al. The role of endoscopy in gastroduodenal obstruction and gastroparesis. *Gastrointest Endosc.* 2011; 74(1):13-21.
12. ASGE Standards of Practice Committee; Khashab MA, Vela MF, Thosani N, et al. ASGE guideline on the management of achalasia. *Gastrointest Endosc.* 2020; 91(2):213-227.
13. ASGE Standards of Practice Committee; Muthusamy VR, Lightdale JR, Acosta RD, et al. Role of endoscopy in the management of GERD. *Gastrointest Endosc.* 2015; 81(6):1305-1310.
14. ASGE Standards of Practice Committee; Pasha SF, Acosta RD, Chandrasekhara V, et al. The role of endoscopy in the evaluation and management of dysphagia. *Gastrointest Endosc.* 2014; 79(2):191-201.
15. ASGE Standards of Practice Committee; Qumseya B, Sultan S, Bain P, et al. ASGE guideline on screening and surveillance of Barrett's esophagus. *Gastrointest Endosc.* 2019; 90(3):335-359.
16. ASGE Standards of Practice Committee; Wani S, Qumseya B, Sultan S, et al. Endoscopic eradication therapy for patients with Barrett's esophagus-associated dysplasia and intramucosal cancer. *Gastrointest Endosc.* 2018; 87(4):907-931.
17. Brethauer SA, Kothari S, Sudan R, et al. Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force. *Surg Obes Relat Dis.* 2014;10(5):952-972.
18. Camilleri M, Kuo B, Nguyen L, et al. ACG clinical guideline: gastroparesis. *Am J Gastroenterol.* 2022; 117(8):1197-1220.
19. De Palma, GD., Forestieri, P. Role of endoscopy in the bariatric surgery of patients. *World J Gastroenterol.* 2014; 20(24):7777-7784.
20. DeVault, KR., Castell, DO. American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. *Am J Gastroenterol.* 2005;100(1):190-200.
21. Gomez, V., Bhalla, R., Heckman, MG., Florit, PT., Diehl, NN., Rawal, B., Lynch, SA., Loeb, DS. Routine screening endoscopy before bariatric surgery: is it necessary? *Bariatric Surg Pract Patient Care.* 2014; 9(4):143-149.
22. Greenwald, DA., Cohen, J. Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy). In: UpToDate, Howell, DA (Ed). UpToDate, Waltham, MA. Accessed October 19, 2023.
23. Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters clinical guidelines for the management of eosinophilic esophagitis. *Gastroenterology.* 2020; 158(6):1776-1786.
24. Ikenberry SO, Harrison ME, Lichtenstein D, et al.; ASGE Standards of Practice Committee. The role of endoscopy in dyspepsia. *Gastrointest Endosc.* 2007; 66(6):1071-1075.
25. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. *Gastroenterology.* 2008; 135(4):1383-1391.
26. Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol.* 2022; 117(1):27-56.
27. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol.* 2013; 108(3):308-328.
28. Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. *Am J Gastroenterol.* 2017; 112(7):988-1013.
29. No authors listed. Endoscopy. The Merck Manual Online. Porter RS, Kaplan JL, Homeier BP, Beers MH, eds. Whitehouse Station, NJ: Merck Research Laboratories; updated February 2013. Available at: <http://www.merck.com/mmpe/sec02/ch009/ch009c.html>. Accessed October 19, 2023.

30. Shaheen NJ, Falk GW, Iyer PG, et al. ACG clinical guideline: diagnosis and management of Barrett's esophagus. *Am J Gastroenterol*. 2016; 111(1):30-50.
31. Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. *Am J Gastroenterol*. 2022; 117(4):559-587.
32. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. *Gastroenterology* 2011; 140(3):1084-1091.
33. Vaezi MF, Pandolfino JE, Yadlapati RH, et al. ACG clinical guidelines: diagnosis and management of achalasia. *Am J Gastroenterol*. 2020; 115(9):1393-1411.
34. Wald, A. Etiology and evaluation of chronic constipation in adults. In: UpToDate, Talley, NJ (Ed). UpToDate
35. Yadlapati R, Gyawali CP, Pandolfino JE. AGA clinical practice update on the personalized approach to the evaluation and management of GERD: expert review. *Clin Prac Update*. 2022; 20(5):984-994.
36. Yang J, Gurudu SR, Koptiuch C, et al. ASGE guideline on the role of endoscopy in familial adenomatous syndromes. *Gastrointest Endosc*. 2020; 91(5):963-982.e2.
37. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol*. 2015;110(2):223. (Screening for esophageal varices and tylosis and FAP and Barrett's screening and NO FAP screening if genetic testing is negative)
38. Giardiello, Francis M et al. Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer, Diseases of the Colon & Rectum 57(8):p 1025-1048, August 2014. (Lynch Syndrome)
39. Evans JA, Early DS, Fukami N, et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. ASGE Standards of Practice Committee, Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy. *Gastrointest Endosc*. 2012;76(6):1087. (Severe esophageal injury from caustic ingestion)
40. Stuart J Spechler, MD, Rhonda F Souza, MD. [UpToDate: Barrett's esophagus: surveillance and management.](#)

## Endnotes

---

<sup>1</sup> Based on expert opinion